Data

A phase 1 study of Olaparib, a poly ADP-ribose polymerase-1 (PARP) inhibitor, in combination with metronomic cyclophosphamide in patients with metastatic BRCA-associated cancer, triple negative breast cancer or serous ovarian cancer (ANZ 1103 SOLACE)

Health Data Australia Contributor Records
Breast Cancer Trials (BCT) ; Lee, Chee ; Breast Cancer Trials (BCT)
Viewed: [[ro.stat.viewed]] Cited: [[ro.stat.cited]] Accessed: [[ro.stat.accessed]]
ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Adc&rfr_id=info%3Asid%2FANDS&rft_id=info:doi10.58080/XR79-ZH98&rft.title=A phase 1 study of Olaparib, a poly ADP-ribose polymerase-1 (PARP) inhibitor, in combination with metronomic cyclophosphamide in patients with metastatic BRCA-associated cancer, triple negative breast cancer or serous ovarian cancer (ANZ 1103 SOLACE)&rft.identifier=http://doi.org/10.58080/XR79-ZH98&rft.publisher=Breast Cancer Trials (BCT)&rft.description=* Dataset for 32 patients with metastatic triple negative breast cancer or metastatic breast cancer and documented BRCA1or BRCA2 mutation (9 breast cancer patients) or high grade serous epithelial ovarian cancer with or without documented BRCA1 or BRCA2 mutation (23 ovarian cancer patients). * Determine maximum tolerated dose of olaparib in combination with metronomic oral cyclophosphamide for maximum of 8 cycles of treatment (1 cycle = 21 days) * Response rate, progression free survival, overall survival data.&rft.creator=Breast Cancer Trials (BCT) &rft.creator=Lee, Chee &rft.creator=Breast Cancer Trials (BCT) &rft.date=2023&rft.relation=https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12613000924752&rft_subject=Cancer therapy (excl. chemotherapy and radiation therapy)&rft.type=dataset&rft.language=English Access data via landing page
Cite Saved to MyRDA Save to MyRDA

Full description

* Dataset for 32 patients with metastatic triple negative breast cancer or metastatic breast cancer and documented BRCA1or BRCA2 mutation (9 breast cancer patients) or high grade serous epithelial ovarian cancer with or without documented BRCA1 or BRCA2 mutation (23 ovarian cancer patients). * Determine maximum tolerated dose of olaparib in combination with metronomic oral cyclophosphamide for maximum of 8 cycles of treatment (1 cycle = 21 days) * Response rate, progression free survival, overall survival data.

Notes

HeSANDA 1.0.0

Issued: 2019

This dataset is part of a larger collection

Click to explore relationships graph
Help

Related Publications

Subjects
Cancer therapy (excl. chemotherapy and radiation therapy) |

User Contributed Tags    

Login to tag this record with meaningful keywords to make it easier to discover

Other Information
Identifiers
ACN 633 798 857